Table 2.
Characteristics of patients with NBNC-HCC stratified according to dates of study period
| 1992–2009 | 2010–2018 | P value | |
|---|---|---|---|
| n = 204 | n = 310 | 2010–2018 versus 1992–2009 | |
| Age (years) | 67 (21–85) | 72 (22–90) | < 0.001 |
| Sex (male/female) | 163/41 | 254/56 | NS |
| Alcohol consumption | 127 (62.2%) | 203 (65.4%) | NS |
| Antibody to hepatitis B core antigen | 83 (40.6%) | 96 (30.9%) | 0.023 |
| Body mass index (kg/m2) | 23.8 (14.3–38.9) | 23.9 (15.3–41.2) | NS |
| Diabetes mellitus | 99 (48.5%) | 187 (60.3%) | 0.008 |
| Hypertension | 99 (48.5%) | 178 (57.4%) | 0.046 |
| Hyperlipidemia | 80 (39.2%) | 167 (53.8%) | 0.001 |
| ALT (IU/L) | 47 (8–435) | 48 (6–388) | NS |
| Platelet counts (× 104/μL, median) | 15.1 (3.5–49.1) | 17.9 (2.7–57.3) | 0.013 |
| FIB-4 index | 4.37 (0.67–28.31) | 3.61 (0.25–22.34) | 0.026 |
| ALBI grade 1/2/3 | 93/96/15 | 138/146/26 | NS |
| Child–Pugh grade A/B/C | 151/42/11 | 231/63/16 | NS |
| Antinuclear antibody | 23 (11.2%) | 45 (14.5%) | NS |
| Antimitochondrial antibodies | 9 (4.4%) | 6 (1.9%) | NS |
Continuous data are presented as medians and range, and categorical data are presented as numbers of patients
NBNC negative for hepatitis B surface antigen and antibody to hepatitis C virus, ALT alanine aminotransferase, FIB-4 fibrosis-4; ALBI grade albumin-bilirubin grade, NS not significant